The humanized monoclonal antibody S-531011, specific for CCR8, has been evaluated in murine colorectal carcinoma (CT26.WT) and breast carcinoma (EMT6) models, reinforcing tumor immunity through selective intratumoral Treg depletion. This evidence concerns the gene CCR8 and neoplasm.